Multi-target combinatory strategy to overcome tumor immune escape.
10.1007/s11684-022-0922-5
- Author:
Yingyan YU
1
Author Information
1. Department of General Surgery of Ruijin Hospital, Shanghai Institute of Digestive Surgery, and Shanghai Key Laboratory for Gastric Neoplasms, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. yingyan3y@sjtu.edu.cn.
- Publication Type:Review
- Keywords:
combination therapy;
immune checkpoints;
immune escape;
immune-related adverse events;
multi-target
- MeSH:
Combined Modality Therapy;
Humans;
Immune Checkpoint Inhibitors;
Immunotherapy;
Melanoma/drug therapy*;
Tumor Escape
- From:
Frontiers of Medicine
2022;16(2):208-215
- CountryChina
- Language:English
-
Abstract:
Immune therapy has become the fourth approach after surgery, chemotherapy, and radiotherapy in cancer treatment. Many immune checkpoints were identified in the last decade since ipilimumab, which is the first immune checkpoint inhibitor to cytotoxic T-lymphocyte associated protein 4, had been approved by the US Food and Drug Administration (FDA) for the treatment of unresectable or metastatic melanoma in 2011. The use of several antibody drugs that target PD1/PD-L1 for various cancer treatments has been approved by the FDA. However, fewer people are benefitting from immune checkpoint inhibitor treatment in solid cancers. Approximately 80% of patients do not respond appropriately because of primary or acquired therapeutic resistance. Along with the characterization of more immune checkpoints, the combinatory treatment of multiimmune checkpoint inhibitors becomes a new option when monotherapy could not receive a good response. In this work, the author focuses on the combination therapy of multiple immune checkpoints (does not include targeted therapy of oncogenes or chemotherapy), introduces the current progression of multiple immune checkpoints and their related inhibitors, and discusses the advantages of combination therapy, as well as the risk of immune-related adverse events.
